We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Here’s what I’d have now by investing £1,000 in AstraZeneca shares 5 years ago

AstraZeneca shares have soared over five years, making them one of the FTSE 100’s biggest successes. But what if I’d bought this stock in mid-June 2018?

| More on:
Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Some investors see the UK stock market as a backwater of old-economy businesses. Yet it also includes a few outstanding global outfits, such as biopharma group AstraZeneca (LSE: AZN). Anyone owning these shares over the past five years has made out like a bandit.

The shares soar

I don’t own any stock in this great British success story. But how I wish I’d held AstraZeneca stock for many years. Since the global financial crisis of 2007-09, the share price has pushed relentlessly higher.

XXX

Here’s how it has performed over eight periods:

One week-2.1%
One month-4.1%
Three months+6.6%
Six months+1.3%
One year+18.1%
Two years+37.9%
Three years+40.4%
Five years+111.3%

Apart from recent weakness, the path of the AstraZeneca share price is clear. Over six periods ranging from three months to five years, the stock has produced positive returns.

Even better, it has more than doubled in a half-decade — a period when the FTSE 100 lost 0.7%. What’s more, these figures exclude cash dividends, which recently started rising at the group.

Happy shareholders

Based on Thursday’s closing price of 11,686p, the stock is 8.9% below its 52-week high of 12,828.45p, hit on 8 March. But its strength means that it’s also 23% above its 52-week low of 9,499.21p, set on 20 October 2022.

These strong returns over sustained periods have made AstraZeneca one of the best performers among large-cap shares. Today, the group is worth £178.4bn, making it the second-largest company on the London stock market.

Moreover, its bumper return of +111.3% in five years makes it the FTSE 100’s second-best performer over this period. Brilliant.

Investing five years ago

Let’s say I had the foresight, skill or luck to invest, say, £1,000 in AstraZeneca stock five years ago. How much would I be sitting on today?

A five-year return of 111.3% would boost my initial investment to £2,113 today. But what about those dividends I mentioned earlier? Here are the group’s cash payouts for the last five financial years:

Year20222021202020192018
Total dividend$2.90$2.87$2.80$2.80$2.80

As an multinational corporation, AstraZeneca payouts out dividends in US dollars. Over the past five years, cash dividends total $14.17. Converted into pounds sterling at the current exchange rate of $1.2775 to £1, this comes to £11.09.

Investing £1,000 in mid-2018 would have bought me roughly 19 AstraZeneca shares. Total dividends paid on this shareholding over five years come to £210.71.

Now I have my answer. Buying £1,000 of this FTSE 100 star’s shares in mid-June 2018 would be worth £2,323.71 today. That’s a handsome return of 132.4%.

I won’t buy this stock now

Finally, AstraZeneca stock trades at a super-premium rating to the wider FTSE 100. It has a price-to-earnings ratio of 48.13, which is about four times the Footsie’s rating.

Also, the current dividend yield of 2.1% a year is well below the index’s yearly cash yield of 3.7%. This is a bit too pricey for me, despite AstraZeneca’s ongoing success and future prospects. And in any event, a lack of cash also prevents me from buying the shares today!

Cliff D'Arcy has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »